ストックスクリーナーアプリを入手
26.87
0.11%
-0.03
アフターアワーズ：
26.65
-0.22
-0.82%
前日終値:
$26.90
開ける：
$27.09
24時間の取引高:
103.56K
Relative Volume:
0.53
時価総額：
$696.68M
収益：
-
当期純損益:
$11.77M
株価収益率:
-173.69
EPS:
-0.1547
ネットキャッシュフロー:
$-19.23M
1週間 パフォーマンス:
-0.85%
1か月 パフォーマンス:
+0.52%
6か月 パフォーマンス:
+69.63%
1年 パフォーマンス:
+60.13%
1日の値動き範囲:
$26.65
$27.68
1週間の範囲:
$25.10
$27.68
52週間の値動き範囲:
$12.12
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-15 | 開始されました | Jefferies | Buy |
| 2023-12-04 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-17 | 開始されました | Truist | Buy |
| 2023-10-31 | 開始されました | Guggenheim | Buy |
| 2023-10-25 | 開始されました | Piper Sandler | Overweight |
| 2022-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
すべてを表示
Tourmaline Bio Inc (TRML) 最新ニュース
AlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio shares get buy rating on IL-6 study optimism - Investing.com Canada
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, Q - GuruFocus.com
The Best Curling Irons, Based On Several Months Of Testing - Forbes
Tourmaline Bio to Present at Upcoming Investor Conferences - The Manila Times
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Declines By 20.0% - MarketBeat
Cantor Fitzgerald Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML) - MarketBeat
Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to “Strong-Buy” - Defense World
Tourmaline Bio (NASDAQ:TRML) Shares Up 6.3%Here's What Happened - MarketBeat
Tourmaline Bio Insiders Placed Bullish Bets Worth US$643.3k - Simply Wall St
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to Strong-Buy - MarketBeat
Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com Canada
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpStill a Buy? - MarketBeat
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - The Manila Times
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - The Manila Times
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in ... - The Bakersfield Californian
TRMLTourmaline Bio, Inc. Latest Stock News & Market Updates - StockTitan
Investing in Tourmaline Bio Inc (TRML): What You Must Know - Knox Daily
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting (NASDAQ:TRML) - Seeking Alpha
Cubist Systematic Strategies LLC Purchases Shares of 37,861 Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Gap Down – Time to Sell? - Defense World
Tourmaline Bio (NASDAQ:TRML) Shares Gap DownTime to Sell? - MarketBeat
Guggenheim reiterates Buy on Tourmaline Bio shares, keeps price target By Investing.com - Investing.com UK
Tourmaline Bio to present research at Cardiometabolic Congress By Investing.com - Investing.com South Africa
Tourmaline Bio to present research at Cardiometabolic Congress - Investing.com
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - The Manila Times
Tourmaline Bio announces CMO resignation By Investing.com - Investing.com South Africa
Tourmaline Bio announces CMO resignation - Investing.com India
Tourmaline Bio’s Chief Medical Officer Resigns Amicably - TipRanks
Tourmaline Bio, Inc. Announces Resignation of Yung Chyung as Chief Medical Officer,Effective October 31, 2024 - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Marquette Asset Management LLC Raises Stake in Vera Bradley, Inc. (NASDAQ:VRA) - Defense World
Tourmaline Bio (NASDAQ:TRML) Stock Price Down 4.3%Should You Sell? - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading 6.4% HigherStill a Buy? - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Trading 6.4% Higher – What’s Next? - Defense World
Tourmaline Bio forms advisory board for heart drug By Investing.com - Investing.com South Africa
Tourmaline Bio forms Cardiovascular Scientific Advisory Board - TipRanks
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board - The Manila Times
Algert Global LLC Has $513,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
There is no way Tourmaline Bio Inc (TRML) can keep these numbers up - SETE News
Keeping an Eye on Tourmaline Bio Inc (TRML) After Insider Trading Activity - Knox Daily
Did Tourmaline Bio Inc (TRML) perform well in the last session? - US Post News
Keeping an Eye on PubMatic Inc (PUBM) After Insider Trading Activity - Knox Daily
Recent Insider Activity Suggests Potential Gains for Neogenomics Inc. (NEO) - Knox Daily
Crew Energy Inc. Announces Completion of Acquisition By Tourmaline Oil Corp. - Yahoo Finance
Graves’ Disease Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight - The Globe and Mail
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Boosted by Blue Owl Capital Holdings LP - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Rhumbline Advisers - MarketBeat
Tourmaline Bio Inc (TRML) 財務データ
収益
当期純利益
現金流量
EPS
Tourmaline Bio Inc (TRML) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
| MCDADE MARK | Director |
Jan 29 '24 |
Buy |
32.50 |
100,000 |
3,250,000 |
448,431 |
| Kulkarni Sandeep Chidambar | CEO |
Nov 17 '23 |
Buy |
16.99 |
4,000 |
67,960 |
729,735 |
| Thiara Parvinder | Director |
Nov 17 '23 |
Buy |
17.31 |
1,000 |
17,310 |
83,782 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):